Blood Filter for the Treatment of COVID-19

Is removing SARS-CoV-2 from the blood sufficient to decrease the severity of critically ill COVID patients? This clinical trial aims to test the efficacy of a new blood filter for the treatment of COVID-19


About Seraph 100

This system developed by ExThera Medical is able to bind to microorganisms in the blood and decrease the amount of viruses or bacteria present.

The Seraph 100 filter consists of a set of small particles made of a material similar to the heparan sulfate in cells. This technology works in a similar way to a hemodialysis system, filtering the blood, with the objective that the microorganisms bind to the filter and are eliminated from the bloodstream. A session of about 4-6h would be enough to clean a large part of the pathogens found in the blood.

This technology was tested by the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense.

Description of the Study:

  • Title: Clinical Trial Testing the Efficacy of a New Blood Filter for the Treatment of COVID-19.
  • Principal Investigators: Ricard Ferrer Roca, Pilar Giron Espot, Tatiana Acero Bailen and Juan Carlos Ruiz Rodríguez.
  • Centers of Implementation: Hospital Vall d’Hebron and Hospital Clínico San Carlos de Madrid.
  • Study Population: COVID-19 critically ill patients who are mechanically ventilated and present, in addition to respiratory dysfunction, dysfunction in some other organ.
  • Study Type: Multicenter clinical trial.

Objectives of the Study:

Principal Objective: To study whether the Seraph 100 filter can decrease the severity of critically ill patients with COVID-19.

More about this Study:

The Seraph 100, like other types of filters that have been used for years in Intensive Care Units, is not only capable of binding microorganisms but also inflammatory mediators.

The purification system is similar to dialysis, but in this case it is viral particles that may be present in the blood that are purified by the filter.

So far, no side effects associated with the use of this system have been observed, so the researchers consider that it could be a novel treatment opportunity for all those patients critical for infections of different types.

Hospital Vall D Hebron
Logo Vector Hospital Clinico San Carlos 1
1519892479861
3fn5olby400x400

Other Clinical Trials:

Un bain de bouche antiviral et COVID-19

L'utilisation d'un bain de bouche contenant de la β-cyclodextrine et du citrox (bioflavonoïdes) (CDCM), disponible en pharmacie, permet de réduire la charge virale du SRAS-CoV-2…

Influence du sexe sur les anticorps neutralisants contre le SARS-CoV-2

Cette étude vise à déterminer les différences dans l'évolution de la réponse immunitaire dans les mois qui suivent l'infection par le SARS-CoV-2 chez les hommes…

COVIDAir : une nouvelle technologie pour détecter les patients COVID-19

Cette étude vise à déterminer la validité d'une nouvelle méthode de détection du COVID-19 par la caractérisation des molécules présentes dans l'air expiré.

ANTICOV Study : COVID-19 en Afrique

Collaborez avec l’étude ANTICOV et contribuez à traiter la COVID-19 en Afrique.

Progestérone pour traiter le COVID-19

Est-ce que les hormones sexuelles peuvent aider les hommes survivre le COVID-19 ? Cette étude a pour objectif évaluer la sécurité et l’efficacité de la…

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

COnV-ert study, convalescent plasma to stop COVID-19

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the…

CombivacS

Clinical trial designed to evaluate the safety and immunogenicity of a dose of Comirnaty vaccine (Pfizer) in people who have previously received a dose of…

Pediatric COVID vaccination clinical trial

This pediatric clinical trial aims to test the safety, tolerability and immunogenicity of Pfizer's COVID vaccine in children under 12 years of age.

LacCOVID Study

The LacCOVID study has shown that milk from lactating women who have been vaccinated with Pfizer-BioNTech contains specific antibodies against the SARS-CoV-2 coronavirus.